Ex Vivo
Compound Screening
Enabling personalized treatment decisions based on functional ex vivo drug screening.
Drug Screening Platform
High troughput screening for precision medicine approaches
CBmed’s drug screening platform is a highly versatile screening system that seamlessly integrates both high-content and high-throughput capabilities. The core robotic system enables the fast and standardized handling of 384 well cell culture plates. The platform offers a highly precise compound transfer via an acoustic system (Labcyte Echo 650), an automated bulk dispensing and plate washing system, a cell incubator and plate reader capable of measuring fluorescence, absorbance, and luminescence. Additionally, it houses a Revity Operetta high-content automated confocal microscope for more advanced analyses. Comprehensive software provides maximum flexibility in assay development, and a Luminex FlexMap 3D reader is available for gene expression-based screening.
The entire system is safely housed in a HEPA-filtered environment, ensuring a sterile and controlled environment for the experiments. This high level of automation not only improves precision and reproducibility, but also enables high-throughput screening. By reducing manual tasks, the platform supports efficient and effective screening on a large scale, accelerating drug discovery and development.
Patient Derived Tumour Cells (PDCs)
Using patient derived tumor cells for personalized treatment recommendations
Our drug screening approach utilizing short-term cultured patient derived tumour cells (PDCs) for ex vivo compound screening. Since short-term cultured PDC’s (2D and 3D culture) preserve many aspects of a tumour’s characteristics and heterogeneity, they represent a highly promising and complimentary method to inform personalized treatment. In our established workflow PDCs are obtained from freshly resected tumour tissue and cultivated for 1-2 weeks prior to drug screening. In contrast to animal model-based applications, complete timely analysis within 3-4 weeks is possible making clinical applicability feasible. The system which we employ has been successfully for the highly standardized testing of up multiple compounds across different concentrations and has been established with highest quality control standards in our central laboratory (CBmed, Graz)sing patient derived tumor cells for personalized treatment recommendations
Integrating results from our ex vivo drug screening platform that utilizes patient-derived tumor cells into clinical decision-making will facilitate the development of highly effective, tailor-made therapies. This approach minimizes adverse effects and advances the application of precision medicine for personalized cancer treatment.
The Team Behind Drug Screening
Meet our team of experts, delivering innovative solutions with passion and precision.
